Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chapman

Showing results (51-60 of 320) with videos related to

Pageof 32
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|July 9, 2004
Vitamin E is not deficient in human atherosclerotic plaquesAnatol Kontush, M John Chapman, Roland Stocker
Journal of Lipid Research|April 2, 2013
Unraveling the complexities of the HDL lipidomeAnatol Kontush, Marie Lhomme, M John Chapman
Criminal Behaviour and Mental Health : CBMH|May 20, 2014
Cannabis use among juvenile detainees: typology, frequency and associationElena L Grigorenko, Laurel Edwards, John Chapman
Pharmacogenomics|February 22, 2011
Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapyPhilippe Couvert, M John Chapman, Alain Carrié
Nature Clinical Practice. Cardiovascular Medicine|April 24, 2008
Spotlight on HDL-raising therapies: insights from the torcetrapib trialsAnatol Kontush, Maryse Guérin, M John Chapman
Transfusion|April 19, 2003
Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red lightAnna-Maija Suontaka, Margareta Blombäck, John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology|August 16, 2003
Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stressAnatol Kontush, Sandrine Chantepie, M John Chapman
Pharmacology & Therapeutics|February 13, 2025
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?Alberto Corsini, Henry N Ginsberg, M John Chapman
Transfusion|February 14, 2004
Inactivation of mycoplasma species in blood by INACTINE PEN110 processBoris Zavizion, Andrei Purmal, John Chapman, et al.
Pharmacology & Therapeutics|May 20, 2026
Bioactive lipids in plasma and atherogenic apoB-containing lipoproteins: Effects of statins and PCSK9 inhibitors and relevance to residual cardiovascular riskM John Chapman, Patrice Therond, Peter J Meikle
Pageof 32

Showing results (51-60 of 320) with videos related to

Sort By:
Pageof 32
Arteriosclerosis, Thrombosis, and Vascular Biology|July 9, 2004
Vitamin E is not deficient in human atherosclerotic plaquesAnatol Kontush, M John Chapman, Roland Stocker
Journal of Lipid Research|April 2, 2013
Unraveling the complexities of the HDL lipidomeAnatol Kontush, Marie Lhomme, M John Chapman
Criminal Behaviour and Mental Health : CBMH|May 20, 2014
Cannabis use among juvenile detainees: typology, frequency and associationElena L Grigorenko, Laurel Edwards, John Chapman
Pharmacogenomics|February 22, 2011
Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapyPhilippe Couvert, M John Chapman, Alain Carrié
Nature Clinical Practice. Cardiovascular Medicine|April 24, 2008
Spotlight on HDL-raising therapies: insights from the torcetrapib trialsAnatol Kontush, Maryse Guérin, M John Chapman
Transfusion|April 19, 2003
Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red lightAnna-Maija Suontaka, Margareta Blombäck, John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology|August 16, 2003
Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stressAnatol Kontush, Sandrine Chantepie, M John Chapman
Pharmacology & Therapeutics|February 13, 2025
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?Alberto Corsini, Henry N Ginsberg, M John Chapman
Transfusion|February 14, 2004
Inactivation of mycoplasma species in blood by INACTINE PEN110 processBoris Zavizion, Andrei Purmal, John Chapman, et al.
Pharmacology & Therapeutics|May 20, 2026
Bioactive lipids in plasma and atherogenic apoB-containing lipoproteins: Effects of statins and PCSK9 inhibitors and relevance to residual cardiovascular riskM John Chapman, Patrice Therond, Peter J Meikle
Pageof 32